Conclusions: LPA and IMA exhibit specific mucin expression profiles, with MUC1 being associated with LPA, while MUC5B, MUC5AC, and MUC6 were associated with IMA. Hnf4α expression and EGFR and KRAS mutations may play a role in mucin expression profiles of these lung adenocarcinoma subtypes.
INTRODUCTION
Lung cancer is the leading cause of cancer mortality worldwide, 85% of cases being non-small cell lung cancers (NSCLC) [1] . The most frequent NSCLC type is invasive lung adenocarcinoma (LUAD), further classified into five subtypes: lepidic, acinar, solid, papillary, or micropapillary [1] . Of these, lepidic predominant adenocarcinomas (LPA) demonstrate specific characteristics: a unique histological pattern, i.e., "lepidic growth". A lepidic growth is defined as a proliferation of type II pneumocytes growing along the native alveolar structure. Compared to other adenocarcinoma subtypes, LPA affects a specific patient population comprising predominantly non-smokers and females [2] .
While LPA is a non-mucinous LUAD, a mucinous variant of LUAD does exist, designated as invasive mucinous adenocarcinoma (IMA). In IMA, tumor cells show a goblet and/or columnar cell morphology, and are tall and well-differentiated with basally-located nuclei, characterized by abundant cytoplasmic mucin. These patients exhibit a worse prognosis than those with LPA, probably due to the aerogenous spreading in IMA, accounting for the common multicentric and bilateral lung involvement [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Distinguishing between LPA and IMA was an aim of the 2015
World Health Organisation (WHO) classification of lung tumours [1] . LPA typically expressed TTF1, which is a marker of type II pneumocytes lineage, whereas IMA do not [14, 15] . Interestingly, a large part of IMA are positive for Hnf4α, a nuclear transcription factor important for goblet cell maturation of cells from colonic mucosae [16] . Hnf4α has been proposed as a diagnostic marker of IMA [14, 16] . LPA is associated with epidermal growth factor receptor gene (EGFR) mutations, whereas IMA is linked to Kirsten-Ras gene (KRAS) mutations and oncogenic fusion genes and never display Epidermal Growth Factor Receptor (EGFR) mutations [15, [17] [18] [19] [20] [21] [22] [23] [24] .
The human mucin (MUC) family has been sub-classified into secreted and transmembrane mucins [25] . The secreted mucins, termed MUC2, MUC5AC, MUC5B, and MUC6, are encoded by the cluster of mucin genes at locus 11p15.5 [26] . The encoded mucins form a physical barrier for the epithelial cells that line the respiratory and digestive tracts. The transmembrane mucins, such as MUC1, display a single membrane-spanning region, contributing to the protective mucous gel, cellcell interactions and cell signaling [27] .
In normal airways and lung, MUC1, MUC2 and MUC5B mucin genes are expressed in the submucosal glands and MUC1, MUC2, MUC5AC and MUC5B in the surface epithelium [28] . Deregulated mucin expression is observed in carcinomas, potentially enhancing tumor cell survival and growth capacities [25] . Depolarized expression of MUC1 has proven a marker of poor prognosis in lung cancer, its overexpression favoring the proliferation and survival of lung cancer cells, also interacting with EGFR to promote proliferation [25, [29] [30] [31] [32] [33] . Three studies showed an overexpression of MUC5AC and MUC6 in cancer cells from IMA samples [34] [35] [36] [37] [38] . The role of MUC5AC, MUC5B, and MUC6 in lung cancer cell biology is not fully understood [39, 40] .
In this study, we sought to describe the pattern of MUC1, MUC2, MUC5B, MUC5AC, and MUC6 protein expression in IMA and LPA, along with their relationship with clinical characteristics and common driver oncogenes.
MATERIALS AND METHODS

Patients
Between January 1992 and December 2012, 52 IMA (n=25) or LPA (n=27) patients were diagnosed in the respiratory medicine department of Tenon Hospital (AP-HP, Paris, France) and underwent surgery. All diagnoses were reviewed by a lung pathologist (MA) based on the 2015 WHO classification [1] . Clinical findings at diagnosis and follow-up data were recorded. All patients signed an informed consent form for the research, authorizing analysis of their biological samples. This study was approved by our hospital's human research ethics committee.
EGFR, KRAS, BRAF, and HER2 mutation analyses
For each formalin-fixed paraffin-embedded (FFPE) specimen, a 3μm tissue section was stained with hematoxylin and eosin (H and E), and the percentage of tumor cells was assessed by light microscopy. Following DNA isolation (Qiagen, Courtaboeuf, France) from three 20µm tissue sections, EGFR mutations pG719S, pT790M, and pL858R (exons 18, 20, and 21, respectively), KRAS mutations pG12S, pG12R, pG12C, pG12A, pG12V, and pG13D (exon 2), as well as BRAF mutations pV600E and pV600K (exon 15) were detected by means of allele specific genotyping using 
Mucin, TTF1 and Hnf4α immunohistochemistry
Immunostaining of MUC1, MUC2, MUC5B, MUC5AC, MUC6, Hnf4α and TTF1 proteins was performed on 3μm tissue sections, processed by means of a BenchMark ULTRA Ventana® staining module (Roche, Tucson, AZ).
For mucins, antigens were retrieved using the CC1 pH 8.8 ethylene-diaminetetraacetic acid (EDTA) antigen retrieval solution (Ventana Medicals System). The primary monoclonal antibodies against MUC1 (clone Ma695, 1/400, Novocastra), MUC2 (clone cp58, 1/50, Novocastra), MUC5B (LUM-5B1 clone, 1/800), MUC5AC
(clone CLH2, 1/50, Novacastra), and MUC6 (clone CLHH5, 1/50, Novacastra) were incubated for 36 minutes at 37°C. We used the Ultra View DAB detection kit® (Ventana Medicals System, Roche Group).
For Hnf4α, antigens were retrieved using the DAKO pH9 EDTA antigen retrieval solution. The primary monoclonal antibodies against Hnf4α (mouse anti-human Hnf4α, clone H1415, 1/200, Novex Life Technologies) was incubated for 90 minutes at room temperature. We used DAKO mouse Envision+ System-HRP Labelled Polymer for detection [16] . A positive HNF4a reaction was marked and unequivocal, and we classified the immunoreaction as either positive or negative.
For TTF1, heat-induced epitope retrieval at pH 6 was used. We used the primary monoclonal antibodies against TTF1 (clone 8G7G3/1, 1/100, DAKO) and the Ultra View DAB detection kit® for TTF-1 detection (Ventana Medicals System, Roche Group). TTF-1 staining was scored as the percentage of positive tumor cells per slide, from 0 to 100%, and a score of 10% was chosen as the threshold for positivity.
Three investigators (MD, MA, and NM), blinded to the clinicopathological variables, independently evaluated the immunostaining process for mucins, coming to a strong consensus. Scores (scale: 0-300) were calculated by multiplying the percentage of positive-stained cells (0-100% by 5% increment) by the staining intensity (1+,2+ or 3+). Tumor samples were considered positive when the immunostaining score was ≥10. All our findings were processed using SPSS 20.0 software (IBM Corporation).
Statistical analysis
RESULTS
Patient and tumor characteristics
The clinical and molecular findings of all 52 patients (IMA: n=25; LPA: n=27) have been summarized in Table 1 . Females accounted for 48% of the cases, non-smokers for 27%. Compared to LPA, patients with IMA were more frequently non-smokers (p=0.04) and exhibiting KRAS mutations (p=0.009), none exhibited EGFR mutation (p=0.024). HER2 mutation was detected in one, a Caucasian female heavy-smoker with LPA. Oncogenic rearrangements were identified in three patients, all IMA cases:
one ALK rearrangement in a Caucasian male smoker, one ROS1 rearrangement in a
Caucasian female non-smoker, and one NRG1 rearrangement in an Asian female non-smoker. All driver oncogenes were mutually exclusive. Figure  1I ).
Mucin expression according to histological subtype
MUC1, MUC5B, MUC5AC, and MUC6 expression in IMA and LPA patients was compared (Table 2, Figure 2 ).
MUC1 was more commonly expressed in LPA samples compared to those of IMA (p=0.033) ( Table 2) Overall, the IMA samples frequently expressed MUC5B and MUC5AC, and sometimes MUC6, with MUC1 expression less common. LPA samples widely expressed MUC1, sometimes MUC5B, and rarely MUC5AC and MUC6. 
Mucin expression according to Hnf4α expression
A Hnf4α nuclear staining in the tumor cells was observed in 23% of cases (n=12).
Out of the 25 IMA samples, 11 were Hnf4α-positive and TTF1-negative tumors ( Figure 4A ). Among the 14 remaining Hnf4α-negative IMA, 11 cases were weakly TTF1-positive (10 to 30%) and 3 cases TTF1-negative ( Figure 4A ). All LPA samples were Hnf4α-negative and TTF1-positive but one, a weakly TTF1-positive LPA that exhibited a KRAS mutation ( Figure 4A ). Overall, the Hnf4α-positive IMA samples exhibited a specific pattern of mucins expression with a lack of MUC1 expression and common and strong expression of MUC5AC and MUC6 contrasting with the lack of MUC5AC and MUC6 expression and MUC1 expression in Hnf4α-negative IMA samples.
Mucins expression according to oncogenic driver status
Five patients exhibited EGFR mutation. MUC1 was always strongly expressed in were never detected (Table 3) .
Thirteen patients exhibited KRAS mutation. MUC5B and MUC5AC were more frequently expressed in KRAS-positive tumors (p=0.002, vs., p=0.001 for KRASnegative). MUC5B and MUC5AC staining scores were significantly higher in KRASpositive tumors (Table 3) . Hnf4α was expressed in six KRAS-positive tumors.
In the ALK-(n=1), ROS1-(n=1) and NRG1-positive IMA tumors (n=1), MUC5B was strongly expressed (210, 240 and 240, respectively), MUC 1 was inconstantly expressed (100, 10 and 0, respectively), and MUC5AC was never expressed as well as MUC6. These three rearranged-IMA were Hnf4α-negative and partially TTF1-positive. (100) 15 (100) 18 ( This study demonstrated that IMA is associated with predominantly secreted mucins encoded by the cluster of genes at locus 11p15.5 gene cluster (MUC2, MUC5B, MUC5AC, and MUC6) [26] . As expected, MUC2, which is the intestinal mucin, was detected in only one IMA case [25] . Appropriate external and internal positive controls were used which validated the quality of our assay. Two previous studies had reported MUC2 protein expression, detected by immunochemistry using the same primary antibody as that used in our study [35, 36] . thus supports the belief in its tumor-suppressor capacity in intestinal adenocarcinoma [41, 42] . Our results suggested that MUC2 expression was down-regulated in lepidic adenocarcinoma, with MUC2 therefore potentially offering a tumor suppressor benefit in this histological subtype.
MUC1 overexpression was associated with the LPA subtype and EGFR mutation, found to be mutually exclusive with MUC5B, MUC5AC, and MUC6 expression.
MUC1 overexpression is common in human cancers, particularly lung cancers, and has not been associated with any specific activating mutations. The MUC1-C subunit is an oncogene involved in the tumorigenesis of breast cancer in vitro [43] . In NSCLC, MUC1-C interacts with EGFR, and targeting this subunit suppresses EGFR activation and the downstream AKT and MEK pathways [31] . A combination treatment of afatinib, an irreversible inhibitor of EGFR, and GO-203, which targets MUC1-C, provides a synergistic action that inhibits the growth of NSCLC cells with EGFR mutations and T790M secondary resistance mutation in vitro [44] . Our results demonstrated a correlation between MUC1 overexpression and EGFR mutation, suggesting that this treatment combination could be attractive in EGFR-mutated LPA. In contrast with normal lung, some IMA samples exhibit aberrantly-expressed MUC6.
MUC6 is normally expressed in the pyloric mucus gland, associated with pancreatic and gastric carcinoma [25] . Interestingly, Hnf4α-positive IMA were always TTF1-negative, do not expressed MUC1 and were likely to commonly and strongly expressed MUC5AC and MUC6. This corresponds to the previous observation that IMA from human and mouse exhibit a specific gene expression signature compared to other lung tumors, including aberrant expression of Hnf4α, MUC5B and MUC5AC mucin-producing gastrointestinal and pancreatic cancers [50] . As previously suggested, this aberrant expression supports the hypothesis that IMA originates from a common endodermal precursor cell, with the potential for multicellular differentiation, including the expression of gastric mucins [34, 51, 52] .
The Hnf4α-negative IMA were mostly TTF1-negative and expressed MUC1 as well as MUC5B but exhibited a lack of MUC5AC and MUC6 expression. These cases may be not "pure" IMA and may represent mixed cases with IMA and lepidic proliferation. The three oncogenic fusion-driven IMA belong to these group of Hnf4α-negative and TTF1-positive IMA.
CONCLUSIONS
We have herein provided evidence of a specific expression profile of mucins in IMA and LPA. MUC5B and MUC5AC expression may play an important role in the typical goblet cell phenotype observed in IMA, triggered by KRAS mutation. MUC1 could also be an interesting target in LPA cases with EGFR mutation.
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